User: Guest

HER2 ANTIBODIES

Global Market Trajectory & Analytics

MCP15866

VALIDATED EXECUTIVE ENGAGEMENTS

POOL + OUTREACH

1841
Number of executives repeatedly engaged by snail & email outreach

INTERACTIONS

331
Interactions with Platform & by Email

PARTICIPANTS

74
Unique # Participated

VALIDATIONS

33
Responses Validated*
* Login to view program details and full enterprise executive list.

DATE

JULY 2020

TABLES

63

PAGES

140

EDITION

8

PRICE

USD $4950


GLOBAL EXECUTIVE SURVEY

Impact of Pandemic & Economic Slowdown

Monitor Market Dynamics!

Early March 2020, we reached out to senior enterprise executives who are driving strategy, business development, marketing, sales, product management, technology and operations at competitive firms worldwide. Our ongoing survey is focused on how this will this affect their business ecosystems. We invite you to participate in our survey and add to collective perspectives. Market movements are tracked for 2020, 2021 and broadly for the period of 2022 through 2025. Critical changes are monitored dynamically for the rest of this year. Updated analytics will reflect new and evolving market realities. Our first update scheduled for May 2020 and another in the Fall. Clients receive complimentary updates during 2020. If your company is a recent client for this project, we may have already reached out to your colleagues to participate in our program. If you're an active player in the space but hasn't yet subscribed to our project, we invite you to participate and share your perspectives. Please sign-up here.

Amid the COVID-19 crisis, the global market for HER2 Antibodies estimated at US$12.8 Billion in the year 2020, is projected to reach a revised size of US$22.3 Billion by 2027, growing at a CAGR of 8.3% over the analysis period 2020-2027. Trastuzumab, one of the segments analyzed in the report, is projected to record a 8.7% CAGR and reach US$14.6 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Lapatinib segment is readjusted to a revised 7.9% CAGR for the next 7-year period.
The HER2 Antibodies market in the U.S. is estimated at US$3.8 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$3.7 Billion by the year 2027 trailing a CAGR of 7% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6.9% and 7.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.2% CAGR.
In the global Ado-trastuzumab emtansine segment, USA, Canada, Japan, China and Europe will drive the 7.3% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$775.3 Million in the year 2020 will reach a projected size of US$1.3 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$2.7 Billion by the year 2027.We bring years of research experience to this 8th edition of our report. The 140-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.
Abnova Corporation; Biocon Ltd.; Bio-Techne Coporation; Celltrion, Inc.; Genentech, Inc.; Invivogen; Novartis AG; Pfizer, Inc.
» Segment (Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab, Everolimus)
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World

INSIDER ACCESS PRIVILEGES

Users of our portal have insider access to our data stacks based on project relevance and engagement status. Tiered access is offered to data stacks, managed based on user status - Opt-in, Active Panelist, Inactive Panelist, Active Client or Inactive Client.

ACTIVE CLIENT

INACTIVE CLIENT

ACTIVE PANELIST

INACTIVE PANELIST

OPT-INS

FEATURED COMPANIES

Registration is required to access our data stacks.

WORLD BRANDS

Registration is required to access our data stacks.

EXECUTIVES ENGAGED

Registration is required to access our data stacks.

KEY DIFFERENTIATORS

We are firmly committed to build upon perspectives from global executive insights. These engagements enrich our projects. Our primary research programs are fully validated and accessible by clients. (Its a common industry-wide* practice that no validated primary research is done! For the most part, remote resident analysts curate and write reports drawing on search engine research and data modeling.

* A review of 262 off-the-shelf market report publishers worldwide.

WHAT SETS US APART
Client companies can access multiple features on our MarketGlass™ platform.

Clients have full-stack insider access to our ongoing primary research program. We have a very successful incentive driven primary research program that benefits participating executives regardless of their purchase decision. Our platform presents a unique opportunity to collaborate with peers and review competitors’ inputs and response clusters.

Detailed engagement stats are presented for every company and executive contacted. This is made available for our client reviews. (no other publisher offers this!)

A full-stack access to clients of all primary and secondary source content. This can often run into thousands of pages.

Where relevent and possible we present competitive brands.

Peer-to-peer online interactive collaborations. Allows for team curated bespoke analytics.

Customers can update and build bespoke versions of our analytics. Bespoke updates are fulfilled within a two-day turnaround.

Discretely bounce off queries to participant pool of executives. Our embedded AI selectively pings participants geographically and by domain acumen.

We pride in our commitment to provide support to our clients. We go beyond the scope of the study to get you timely answers.

Unlike the industry’s published PDF’s that are frozen in time from date of release, our research programs are ongoing and dynamic. Our reports are updated whenever there’s a major event impacting the marketplace. Your license offers seamless updates for one year.

All updates are offered for one year from date of your purchase without charge. Clients can opt for annual auto renewal and stay current without interruption.

  
05
1. MARKET OVERVIEW
Global Competitor Market Shares
HER2 Antibodies Competitor Market Share Scenario Worldwide (in %): 2019 & 2025
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
World Recent Past, Current & Future Analysis for HER2 Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2018 through 2025
World Historic Review for HER2 Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in Units for Years 2009 through 2017
World 16-Year Perspective for HER2 Antibodies by Geographic Region - Percentage Breakdown of Unit Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2009, 2019 & 2025
World Recent Past, Current & Future Analysis for Trastuzumab by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2018 through 2025
World Historic Review for Trastuzumab by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in Units for Years 2009 through 2017
World 16-Year Perspective for Trastuzumab by Geographic Region - Percentage Breakdown of Unit Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2009, 2019 & 2025
World Recent Past, Current & Future Analysis for Lapatinib by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2018 through 2025
World Historic Review for Lapatinib by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in Units for Years 2009 through 2017
World 16-Year Perspective for Lapatinib by Geographic Region - Percentage Breakdown of Unit Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2009, 2019 & 2025
World Recent Past, Current & Future Analysis for Ado-trastuzumab emtansine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2018 through 2025
World Historic Review for Ado-trastuzumab emtansine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in Units for Years 2009 through 2017
World 16-Year Perspective for Ado-trastuzumab emtansine by Geographic Region - Percentage Breakdown of Unit Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2009, 2019 & 2025
World Recent Past, Current & Future Analysis for Pertuzumab by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2018 through 2025
World Historic Review for Pertuzumab by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in Units for Years 2009 through 2017
World 16-Year Perspective for Pertuzumab by Geographic Region - Percentage Breakdown of Unit Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2009, 2019 & 2025
World Recent Past, Current & Future Analysis for Everolimus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2018 through 2025
World Historic Review for Everolimus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in Units for Years 2009 through 2017
World 16-Year Perspective for Everolimus by Geographic Region - Percentage Breakdown of Unit Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2009, 2019 & 2025
GEOGRAPHIC MARKET ANALYSIS
UNITED STATES
Market Facts & Figures
US HER2 Antibodies Market Share (in %) by Company: 2019 & 2025
USA Recent Past, Current & Future Analysis for HER2 Antibodies by Segment - Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus Independently Analyzed with Annual Sales Figures in US$ Thousand for the Years 2018 through 2025
USA Historic Review for HER2 Antibodies by Segment - Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017
USA 16-Year Perspective for HER2 Antibodies by Segment - Percentage Breakdown of Value Sales for Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus for the Years 2009, 2019 & 2025
CANADA
Canada Recent Past, Current & Future Analysis for HER2 Antibodies by Segment - Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus Independently Analyzed with Annual Sales Figures in US$ Thousand for the Years 2018 through 2025
Canada Historic Review for HER2 Antibodies by Segment - Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017
Canada 16-Year Perspective for HER2 Antibodies by Segment - Percentage Breakdown of Value Sales for Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus for the Years 2009, 2019 & 2025
JAPAN
Japan Recent Past, Current & Future Analysis for HER2 Antibodies by Segment - Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus Independently Analyzed with Annual Sales Figures in US$ Thousand for the Years 2018 through 2025
Japan Historic Review for HER2 Antibodies by Segment - Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017
Japan 16-Year Perspective for HER2 Antibodies by Segment - Percentage Breakdown of Value Sales for Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus for the Years 2009, 2019 & 2025
CHINA
China Recent Past, Current & Future Analysis for HER2 Antibodies by Segment - Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus Independently Analyzed with Annual Sales Figures in US$ Thousand for the Years 2018 through 2025
China Historic Review for HER2 Antibodies by Segment - Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017
China 16-Year Perspective for HER2 Antibodies by Segment - Percentage Breakdown of Value Sales for Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus for the Years 2009, 2019 & 2025
EUROPE
Market Facts & Figures
European HER2 Antibodies Market: Competitor Market Share Scenario (in %) for 2019 & 2025
Europe Recent Past, Current & Future Analysis for HER2 Antibodies by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2018 through 2025
Europe Historic Review for HER2 Antibodies by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in Units for Years 2009 through 2017
Europe 16-Year Perspective for HER2 Antibodies by Geographic Region - Percentage Breakdown of Unit Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2009, 2019 & 2025
Europe Recent Past, Current & Future Analysis for HER2 Antibodies by Segment - Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus Independently Analyzed with Annual Sales Figures in US$ Thousand for the Years 2018 through 2025
Europe Historic Review for HER2 Antibodies by Segment - Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017
Europe 16-Year Perspective for HER2 Antibodies by Segment - Percentage Breakdown of Value Sales for Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus for the Years 2009, 2019 & 2025
FRANCE
France Recent Past, Current & Future Analysis for HER2 Antibodies by Segment - Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus Independently Analyzed with Annual Sales Figures in US$ Thousand for the Years 2018 through 2025
France Historic Review for HER2 Antibodies by Segment - Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017
France 16-Year Perspective for HER2 Antibodies by Segment - Percentage Breakdown of Value Sales for Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus for the Years 2009, 2019 & 2025
GERMANY
Germany Recent Past, Current & Future Analysis for HER2 Antibodies by Segment - Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus Independently Analyzed with Annual Sales Figures in US$ Thousand for the Years 2018 through 2025
Germany Historic Review for HER2 Antibodies by Segment - Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017
Germany 16-Year Perspective for HER2 Antibodies by Segment - Percentage Breakdown of Value Sales for Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus for the Years 2009, 2019 & 2025
ITALY
Italy Recent Past, Current & Future Analysis for HER2 Antibodies by Segment - Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus Independently Analyzed with Annual Sales Figures in US$ Thousand for the Years 2018 through 2025
Italy Historic Review for HER2 Antibodies by Segment - Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017
Italy 16-Year Perspective for HER2 Antibodies by Segment - Percentage Breakdown of Value Sales for Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus for the Years 2009, 2019 & 2025
UNITED KINGDOM
UK Recent Past, Current & Future Analysis for HER2 Antibodies by Segment - Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus Independently Analyzed with Annual Sales Figures in US$ Thousand for the Years 2018 through 2025
UK Historic Review for HER2 Antibodies by Segment - Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017
UK 16-Year Perspective for HER2 Antibodies by Segment - Percentage Breakdown of Value Sales for Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus for the Years 2009, 2019 & 2025
REST OF EUROPE
Rest of Europe Recent Past, Current & Future Analysis for HER2 Antibodies by Segment - Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus Independently Analyzed with Annual Sales Figures in US$ Thousand for the Years 2018 through 2025
Rest of Europe Historic Review for HER2 Antibodies by Segment - Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017
Rest of Europe 16-Year Perspective for HER2 Antibodies by Segment - Percentage Breakdown of Value Sales for Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus for the Years 2009, 2019 & 2025
ASIA-PACIFIC
Asia-Pacific Recent Past, Current & Future Analysis for HER2 Antibodies by Segment - Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus Independently Analyzed with Annual Sales Figures in US$ Thousand for the Years 2018 through 2025
Asia-Pacific Historic Review for HER2 Antibodies by Segment - Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017
Asia-Pacific 16-Year Perspective for HER2 Antibodies by Segment - Percentage Breakdown of Value Sales for Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus for the Years 2009, 2019 & 2025
REST OF WORLD
Rest of World Recent Past, Current & Future Analysis for HER2 Antibodies by Segment - Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus Independently Analyzed with Annual Sales Figures in US$ Thousand for the Years 2018 through 2025
Rest of World Historic Review for HER2 Antibodies by Segment - Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017
Rest of World 16-Year Perspective for HER2 Antibodies by Segment - Percentage Breakdown of Value Sales for Trastuzumab, Lapatinib, Ado-trastuzumab emtansine, Pertuzumab and Everolimus for the Years 2009, 2019 & 2025
Total Companies Profiled : 5

Click here to request a full table of contents and more details on this project.

INSIDER ACCESS TO

 METHODOLOGY  QUESTIONNAIRE  INFLUENCER NETWORK

Registration is required to access our data stacks.

RESEARCH PANEL

Panelists are carefully chosen based on their domain expertise and market influence.

Participation in our expert panels is only by invitation. Our project focused panels are constituted of senior executives in business strategy, marketing, sales, and product management at competitive companies worldwide. We also welcome individuals from leading management consulting, venture capital, private equity, investment management and related firms with domain expertise and are actively monitoring specific companies or industries. Our panelists bring unique market perspectives and unbiased intelligence to our ongoing research programs.

Our panelists give 30-minutes a month or a one-time 30-minute participation based on their time and willingness.

  • Complimentary previews of full stack research data for participated
  • Insider access to research programs including engagements and stats from other panelists
  • Unlimited research credits of $1000 per participated project
  • Competitive Intelligence Alerts including engagements from other panelists and validated participants worldwide relevant to your company
  • Interact with other panelists via our MarketGlassTM Data Exchange Platform*
  • BlogX - Panelists can use our blogging platform publish their viewpoints on news relevant to their domain expertise. Platform enables panelists to share their viewpoints on current news and events related to their areas domain expertise with timely and insightful blogs*

* Complete details will be shared with panelists upon formal acceptance.

 GLOBAL EXPERT PANEL

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com


Sales queries: Sales@StrategyR.com
Research queries: Info411@StrategyR.com